medical decision support medical decision support
Sign In

Risk Factors for Hemorrhage in a Patient Treated with Ibrutinib

Description

Ibrutinib is a Bruton tyrosine kinase inhibitor that is used to treat several B-cell malignancies. Brown et al identified factors associated with hemorrhage in these patients. The authors are from multiple institutions in the United States and Europe.


Patient selection: therapy with ibrutinib

 

Low-grade hemorrhage (contusion, epistaxis, bruising, petechiae; Grade 1 or 2): occurs in 36% of patient.

High-grade hemorrhage (Grade >= 3) occurs in 4% of patients.

 

Risk factors for hemorrhage:

(1) concurrent therapy with anticoagulants and/or antiplatelet agents and/or supplements with anticoagulant properties

(2) mantle cell lymphoma

(3) trauma or surgery (provoked)


To read more or access our algorithms and calculators, please log in or register.

Specialty